10-K
Annual Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
41 line items · 2 periods
XBRL
| Item | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 359,284,000 | 219,746,000 |
Marketable securities | 29,411,000 | 210,238,000 |
Restricted cash | 0 | 2,633,000 |
Accounts receivable, net | 114,832,000 | 104,211,000 |
Inventory | 73,706,000 | 81,629,000 |
Prepaid expenses and other current assets | 18,789,000 | 16,578,000 |
Total current assets | 596,022,000 | 635,035,000 |
Property and equipment, net | 279,571,000 | 289,328,000 |
Restricted cash | 0 | 4,974,000 |
Operating lease right-of-use assets | 65,361,000 | 69,882,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 16,616,000 | 22,858,000 |
Other noncurrent assets | 3,062,000 | 2,392,000 |
Total assets | 965,143,000 | 1,028,980,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 15,738,000 | 21,599,000 |
Accrued compensation and related benefits | 30,105,000 | 32,675,000 |
Accrued expenses and other current liabilities | 56,648,000 | 59,779,000 |
Deferred revenue | 13,150,000 | 7,867,000 |
2024-01-01 | 13,100,000 | — |
Operating lease liabilities | 11,521,000 | 9,037,000 |
Total current liabilities | 127,162,000 | 130,957,000 |
Operating lease liabilities, noncurrent | 83,849,000 | 86,139,000 |
Deferred revenue, noncurrent | 8,814,000 | 3,165,000 |
Other noncurrent liabilities | 4,275,000 | 2,976,000 |
Total liabilities | 224,100,000 | 223,237,000 |
Stockholders' equity: | ||
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 119,095,362 (Class A 105,038,529, Class B 14,056,833) and 115,195,009 (Class A 96,527,754, Class B 18,667,255) shares issued and outstanding as of December 31, 2023 and 2022, respectively | 2,000 | 2,000 |
Additional paid-in capital | 2,025,890,000 | 1,839,397,000 |
Accumulated deficit | (1,284,420,000) | (1,029,321,000) |
Accumulated other comprehensive loss | (429,000) | (4,335,000) |
Total stockholders’ equity | 741,043,000 | 805,743,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,025,890,000 | 1,839,397,000 |
Accumulated Deficit | (1,284,420,000) | (1,029,321,000) |
Accumulated Other Comprehensive Income (Loss) | (429,000) | (4,335,000) |
Total liabilities and stockholders’ equity | 965,143,000 | 1,028,980,000 |